Waypoint Bio
Agent42Agent Readiness: 42/100. Above median. Measured by StartupHub.ai. Median 41.Trust63Data Trust: 63/100. Above median. Measured by StartupHub.ai. Median 61.AI-native biotech company designing next-generation CAR T therapies for solid tumors.
About
Waypoint Bio is an AI-native biotechnology company focused on leveraging spatial biology and artificial intelligence to develop advanced CAR T therapies specifically for solid tumors. Their approach aims to overcome the limitations of current CAR T treatments, which have shown less efficacy in solid tumors compared to blood cancers. The company utilizes its proprietary AI platform to analyze complex biological data and design more effective and targeted therapeutic solutions.
Key facts
At-a-glance profile data
- Website
- waypointbio.com
- Headquarters
- New York, New York, USA
- Founded
- 2021
- Employees
- 20
- Total funding
- $20M (Series A)
- Business model
- B2B
Funding rounds
| Date | Round | Amount | Lead investors |
|---|---|---|---|
| 1 Jun 2026 | Series A | $20M | Amplify Partners |
Tech stack
Detected on waypointbio.com, last scanned 24 Oct 2026. Run your own scan
- CMS / Builders
- Webflow
- CDN
- Cloudflare
- Email provider
- Google Workspace
Frequently asked
Is Waypoint Bio trustworthy and reputable?
StartupHub's Data Trust & Reputation score for Waypoint Bio is 63 out of 100, a generally safe rating, based on site security posture, privacy practices, malware and phishing checks, and public reputation signals.
How much funding has Waypoint Bio raised?
Waypoint Bio has raised a total of $20M in funding. The most recent round on record is Series A.
How many employees does Waypoint Bio have?
Waypoint Bio has approximately 20 people on record.
